Spotlight
Clinical
News
FDA
CME/CE
Subscribe
- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35
Beginning June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers to treat asthma and chronic obstructive pulmonary disease (COPD). Included are:
- Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
- Combivent Respimat® (ipratropium bromide and albuterol) Inhalation Spray
- Spiriva HandiHaler(tiotropium bromide inhalation powder)
- Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray
- Spiriva® Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray
- Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray
- Striverdi Respimat (olodaterol) Inhalation Spray
The company said in a press release that it will decrease the list price on some of its inhaler products and will continue providing rebates off the list price of its medicines to insurers and pharmacy benefits managers.
Related Videos
Related Content
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Article
Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
